{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:12:42Z","timestamp":1792566762358,"version":"4.5.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Schwannomas are tumors of the nervous system that occur sporadically and in patients with the cancer predisposition syndrome neurofibromatosis type 2 (NF2). Schwannomas and all NF2-related tumors are caused by loss of the tumor suppressor merlin. Using our human in vitro model for schwannoma, we analyzed extracellular signal-regulated kinase 1\/2 (ERK1\/2) and AKT signaling pathways, their upstream growth factor receptors, and their role in schwannoma cell proliferation and adhesion to find new systemic therapies for these tumors that, to date, are very difficult to treat. We show here that human primary schwannoma cells show an enhanced basal Raf\/mitogen-activated protein\/ERK kinase\/ERK1\/2 pathway activity compared with healthy Schwann cells. Due to a strong and prolonged activation of platelet-derived growth factor receptor \u03b2 (PDGFR\u03b2), which is highly overexpressed, ERK1\/2 and AKT activation was further increased in schwannoma, leading to increased proliferation. Using specific inhibitors, we discovered that ERK1\/2 activation involves the integrin\/focal adhesion kinase\/Src\/Ras signaling cascades and PDGFR\u03b2-mediated ERK1\/2 activation is triggered through the phosphatidylinositol 3-kinase\/protein kinase C\/Src\/c-Raf pathway. Due to the complexity of signals leading to schwannoma cell proliferation, potential new therapeutic agents should target several signaling pathways. The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFR\u03b2-mediated ERK1\/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas. We conclude that our schwannoma in vitro model can be used to screen for new therapeutic targets in general and that sorafenib is possible candidate for future clinical trials. [Cancer Res 2008;68(13):5236\u201345]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5849","type":"journal-article","created":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T13:53:53Z","timestamp":1214920433000},"page":"5236-5245","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Dissecting and Targeting the Growth Factor\u2013Dependent and Growth Factor\u2013Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma"],"prefix":"10.1158","volume":"68","author":[{"given":"Sylwia","family":"Ammoun","sequence":"first","affiliation":[{"name":"1Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Flaiz","sequence":"additional","affiliation":[{"name":"1Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ristic","sequence":"additional","affiliation":[{"name":"1Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schuldt","sequence":"additional","affiliation":[{"name":"2Department of Neurology, Zentrum fuer Klinische Forschung, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Oliver","family":"Hanemann","sequence":"additional","affiliation":[{"name":"1Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,7,1]]},"reference":[{"key":"2022061700402806600_B1","doi-asserted-by":"crossref","unstructured":"McClatchey AI, Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev\u20082005; 19: 2265\u201377.","DOI":"10.1101\/gad.1335605"},{"key":"2022061700402806600_B2","doi-asserted-by":"crossref","unstructured":"Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 (see comments). Nature\u20081993; 363: 515\u201321.","DOI":"10.1038\/363515a0"},{"key":"2022061700402806600_B3","doi-asserted-by":"crossref","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell\u20081993; 75: 826.","DOI":"10.1016\/0092-8674(93)90406-G"},{"key":"2022061700402806600_B4","doi-asserted-by":"crossref","unstructured":"Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol\u20082002; 3: 586\u201399.","DOI":"10.1038\/nrm882"},{"key":"2022061700402806600_B5","doi-asserted-by":"crossref","unstructured":"Utermark T, Kaempchen K, Antoniadis G, Hanemann CO. Reduced apoptosis rates in human schwannomas. Brain Pathol\u20082005; 15: 17\u201322.","DOI":"10.1111\/j.1750-3639.2005.tb00095.x"},{"key":"2022061700402806600_B6","doi-asserted-by":"crossref","unstructured":"Utermark T, Kaempchen K, Hanemann CO. Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol\u20082003; 13: 352\u201363.","DOI":"10.1111\/j.1750-3639.2003.tb00034.x"},{"key":"2022061700402806600_B7","doi-asserted-by":"crossref","unstructured":"Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. Glia\u20082008; 56: 506\u201315.","DOI":"10.1002\/glia.20629"},{"key":"2022061700402806600_B8","doi-asserted-by":"crossref","unstructured":"Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1\/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet\u20082003; 12: 1211\u201321.","DOI":"10.1093\/hmg\/ddg146"},{"key":"2022061700402806600_B9","doi-asserted-by":"crossref","unstructured":"Flaiz C, Kaempchen K, Matthies C, Hanemann CO. Actin-rich protrusions and nonlocalized GTPase activation in merlin-deficient schwannomas. J Neuropathol Exp Neurol\u20082007; 66: 608\u201316.","DOI":"10.1097\/nen.0b013e318093e555"},{"key":"2022061700402806600_B10","doi-asserted-by":"crossref","unstructured":"Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell\u20082003; 12: 841\u20139.","DOI":"10.1016\/S1097-2765(03)00382-4"},{"key":"2022061700402806600_B11","doi-asserted-by":"crossref","unstructured":"Hirokawa Y, Tikoo A, Huynh J, et al. A clue to the therapy of neurofibromatosis type 2: NF2\/merlin is a PAK1 inhibitor. Cancer J\u20082004; 10: 20\u20136.","DOI":"10.1097\/00130404-200401000-00006"},{"key":"2022061700402806600_B12","doi-asserted-by":"crossref","unstructured":"Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human schwannoma cells. Oncogene\u20081998; 17: 2195\u2013209.","DOI":"10.1038\/sj.onc.1202141"},{"key":"2022061700402806600_B13","doi-asserted-by":"crossref","unstructured":"Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC. The Ras\/Raf\/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J\u20082004; 23: 3061\u201371.","DOI":"10.1038\/sj.emboj.7600309"},{"key":"2022061700402806600_B14","doi-asserted-by":"crossref","unstructured":"Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG. Integrin \u03b12-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem\u20082006; 281: 8497\u2013510.","DOI":"10.1074\/jbc.M600787200"},{"key":"2022061700402806600_B15","doi-asserted-by":"crossref","unstructured":"Meloche S, Pouyssegur J. The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene\u20082007; 26: 3227\u201339.","DOI":"10.1038\/sj.onc.1210414"},{"key":"2022061700402806600_B16","doi-asserted-by":"crossref","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P. Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res\u20082007; 67: 520\u20137.","DOI":"10.1158\/0008-5472.CAN-06-1608"},{"key":"2022061700402806600_B17","doi-asserted-by":"crossref","unstructured":"Lim JY, Kim H, Jeun SS, Kang SG, Lee KJ. Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. Biochem Biophys Res Commun\u20082006; 340: 1151\u20137.","DOI":"10.1016\/j.bbrc.2005.12.122"},{"key":"2022061700402806600_B18","doi-asserted-by":"crossref","unstructured":"Fraenzer JT, Pan H, Minimo L, Jr., Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol\u20082003; 23: 1493\u2013500.","DOI":"10.3892\/ijo.23.6.1493"},{"key":"2022061700402806600_B19","doi-asserted-by":"crossref","unstructured":"Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A\u20082004; 101: 18200\u20135.","DOI":"10.1073\/pnas.0405971102"},{"key":"2022061700402806600_B20","doi-asserted-by":"crossref","unstructured":"Li Y, Tennekoon GI, Birnbaum M, Marchionni MA, Rutkowski JL. Neuregulin signaling through a PI3K\/Akt\/Bad pathway in Schwann cell survival. Mol Cell Neurosci\u20082001; 17: 761\u20137.","DOI":"10.1006\/mcne.2000.0967"},{"key":"2022061700402806600_B21","doi-asserted-by":"crossref","unstructured":"Meier F, Schittek B, Busch S, et al. The RAS\/RAF\/MEK\/ERK and PI3K\/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci\u20082005; 10: 2986\u20133001.","DOI":"10.2741\/1755"},{"key":"2022061700402806600_B22","doi-asserted-by":"crossref","unstructured":"Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev\u20081999; 79: 1283\u2013316.","DOI":"10.1152\/physrev.1999.79.4.1283"},{"key":"2022061700402806600_B23","doi-asserted-by":"crossref","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med\u20082007; 356: 125\u201334.","DOI":"10.1056\/NEJMoa060655"},{"key":"2022061700402806600_B24","doi-asserted-by":"crossref","unstructured":"Hanemann CO, Rosenbaum C, Kupfer S, Wosch S, Stoegbauer F, Mueller HW. Improved culture methods to expand Schwann cells with altered growth behaviour from CMT1A patients. GLIA\u20081998; 23: 89\u201398.","DOI":"10.1002\/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z"},{"key":"2022061700402806600_B25","doi-asserted-by":"crossref","unstructured":"Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis\u20081998; 5: 55\u201364.","DOI":"10.1006\/nbdi.1998.0179"},{"key":"2022061700402806600_B26","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. Arch Neurol\u20081994; 51: 201\u20137.","DOI":"10.1001\/archneur.1994.00540140115021"},{"key":"2022061700402806600_B27","doi-asserted-by":"crossref","unstructured":"Hanemann CO, Bartelt-Kirbach B, Diebold R, Kampchen K, Langmesser S, Utermark T. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol Appl Neurobiol\u20082006; 32: 605\u201314.","DOI":"10.1111\/j.1365-2990.2006.00769.x"},{"key":"2022061700402806600_B28","doi-asserted-by":"crossref","unstructured":"Milner R, Wilby M, Nishimura S, et al. Division of labor of Schwann cell integrins during migration on peripheral nerve extracellular matrix ligands. Dev Biol\u20081997; 185: 215\u201328.","DOI":"10.1006\/dbio.1997.8547"},{"key":"2022061700402806600_B29","doi-asserted-by":"crossref","unstructured":"Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2\/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem\u20081997; 272: 13189\u201395.","DOI":"10.1074\/jbc.272.20.13189"},{"key":"2022061700402806600_B30","doi-asserted-by":"crossref","unstructured":"Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol\u20082008; 15: 322\u201331.","DOI":"10.1016\/j.chembiol.2008.03.005"},{"key":"2022061700402806600_B31","doi-asserted-by":"crossref","unstructured":"Hehlgans S, Haase M, Cordes N. Signaling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta\u20082007; 1775: 163\u201380.","DOI":"10.1016\/j.bbcan.2006.09.001"},{"key":"2022061700402806600_B32","doi-asserted-by":"crossref","unstructured":"Leu TH, Maa MC. Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397. Oncogene\u20082002; 21: 6992\u20137000.","DOI":"10.1038\/sj.onc.1205904"},{"key":"2022061700402806600_B33","doi-asserted-by":"crossref","unstructured":"Bos JL. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J\u20081998; 17: 6776\u201382.","DOI":"10.1093\/emboj\/17.23.6776"},{"key":"2022061700402806600_B34","doi-asserted-by":"crossref","unstructured":"Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, Parker PJ. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science\u20081998; 281: 2042\u20135.","DOI":"10.1126\/science.281.5385.2042"},{"key":"2022061700402806600_B35","doi-asserted-by":"crossref","unstructured":"Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci\u20082003; 24: 366\u201376.","DOI":"10.1016\/S0165-6147(03)00163-9"},{"key":"2022061700402806600_B36","doi-asserted-by":"crossref","unstructured":"Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem\u20081994; 269: 5241\u20138.","DOI":"10.1016\/S0021-9258(17)37680-9"},{"key":"2022061700402806600_B37","doi-asserted-by":"crossref","unstructured":"Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem\u20081991; 266: 15771\u201381.","DOI":"10.1016\/S0021-9258(18)98476-0"},{"key":"2022061700402806600_B38","doi-asserted-by":"crossref","unstructured":"Bindels RJ, Dempster JA, Ramakers PL, Willems PH, van Os CH. Effect of protein kinase C activation and down-regulation on active calcium transport. Kidney Int\u20081993; 43: 295\u2013300.","DOI":"10.1038\/ki.1993.46"},{"key":"2022061700402806600_B39","doi-asserted-by":"crossref","unstructured":"Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J\u20082004; 384: 449\u201359.","DOI":"10.1042\/BJ20040704"},{"key":"2022061700402806600_B40","doi-asserted-by":"crossref","unstructured":"Schulze KM, Hanemann CO, Muller HW, Hanenberg H. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet\u20082002; 11: 69\u201376.","DOI":"10.1093\/hmg\/11.1.69"},{"key":"2022061700402806600_B41","doi-asserted-by":"crossref","unstructured":"Park CS, Schneider IC, Haugh JM. Kinetic analysis of platelet-derived growth factor receptor\/phosphoinositide 3-kinase\/Akt signaling in fibroblasts. J Biol Chem\u20082003; 278: 37064\u201372.","DOI":"10.1074\/jbc.M304968200"},{"key":"2022061700402806600_B42","doi-asserted-by":"crossref","unstructured":"Haugh JM, Lauffenburger DA. Analysis of receptor internalization as a mechanism for modulating signal transduction. J Theor Biol\u20081998; 195: 187\u2013218.","DOI":"10.1006\/jtbi.1998.0791"},{"key":"2022061700402806600_B43","doi-asserted-by":"crossref","unstructured":"Heinrich R, Neel BG, Rapoport TA. Mathematical models of protein kinase signal transduction. Mol Cell\u20082002; 9: 957\u201370.","DOI":"10.1016\/S1097-2765(02)00528-2"},{"key":"2022061700402806600_B44","doi-asserted-by":"crossref","unstructured":"Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem\u20082005; 280: 36609\u201315.","DOI":"10.1074\/jbc.M502306200"},{"key":"2022061700402806600_B45","doi-asserted-by":"crossref","unstructured":"Hancock JF. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol\u20082003; 4: 373\u201384.","DOI":"10.1038\/nrm1105"},{"key":"2022061700402806600_B46","doi-asserted-by":"crossref","unstructured":"Dong C, Waters SB, Holt KH, Pessin JE. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem\u20081996; 271: 6328\u201332.","DOI":"10.1074\/jbc.271.11.6328"},{"key":"2022061700402806600_B47","doi-asserted-by":"crossref","unstructured":"Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal\u20082003; 15: 463\u20139.","DOI":"10.1016\/S0898-6568(02)00139-0"},{"key":"2022061700402806600_B48","doi-asserted-by":"crossref","unstructured":"Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev\u20082004; 15: 205\u201313.","DOI":"10.1016\/j.cytogfr.2004.03.003"},{"key":"2022061700402806600_B49","doi-asserted-by":"crossref","unstructured":"Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays\u20082000; 22: 818\u201326.","DOI":"10.1002\/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6"},{"key":"2022061700402806600_B50","doi-asserted-by":"crossref","unstructured":"Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol\u20082002; 64: 755\u201363.","DOI":"10.1016\/S0006-2952(02)01135-8"},{"key":"2022061700402806600_B51","doi-asserted-by":"crossref","unstructured":"Stewart HJ, Bradke F, Tabernero A, Morrell D, Jessen KR, Mirsky R. Regulation of rat Schwann cell Po expression and DNA synthesis by insulin-like growth factors in vitro. Eur J Neurosci\u20081996; 8: 553\u201364.","DOI":"10.1111\/j.1460-9568.1996.tb01240.x"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/13\/5236\/2595331\/5236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/13\/5236\/2595331\/5236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:01:11Z","timestamp":1655431271000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/13\/5236\/541031\/Dissecting-and-Targeting-the-Growth-Factor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":51,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2008,7,1]]},"published-print":{"date-parts":[[2008,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5849","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22374393","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374390","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497424","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374399","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497424.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374393.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374396.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374396","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374399.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22374390.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}